Doxy-WISE: Weekly versus event-driven doxycycline post-exposure prophylaxis for STI prevention in MSM and transgender women on HIV PrEP

Phase 3, randomised, open-label trial of doxycycline in sexually transmitted disease (STD), gonorrhea, Chlamydia trachomatis infection and 1 more (2 arms), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: Primary: Incidence rate ratio of NG, CT, and TP infections. Planned start Mar 2026; status: authorised.